The Chinese drug administration handed two drug registration certificates to China Meheco Group's (SHA:600056) subsidiary, China National Pharmaceutical and Healthcare Industry, for sacubitril-valsartan sodium tablets, according to a Shanghai Stock Exchange filing on Tuesday.
The certificates allow the company to market 50 milligrams and 100 milligrams of the anti-heart failure drug, the drugmaker said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments